<DOC>
	<DOCNO>NCT01630174</DOCNO>
	<brief_summary>To evaluate effect concomitant late course accelerate hyperfractionation radiochemotherapy pemetrexed cisplatin patient esophagus cancer</brief_summary>
	<brief_title>IMRT/Pemetrexed/Cisplatin Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Signed informed consent ; 2.Acquired pathological diagnosis ; 3.Life expectancy≥6 month ; 4.Age:1875 year , male female ; 5.General state health : ECOG 0－1 grade ; 6.Without chemotherapy radiotherapy ; 7.Subjects meet follow criterion clinical laboratory : HG≥100g/L , WBC≥3.5X109 /L , neutrophilic leukocyte≥1.5X109 , PLT100X109 /L。CR≤1.5 x N，TB≤2.5XN，AST ALT≤2.5xN，AKP≤2.5XN . 1.Serious infection ; 2.Uncontrollable diabetes ; 3.Other serious disease , myocardial infarction 6 month ; 4 . Participated clinical trial 4 week present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>IMRT , Pemetrexed , Cisplatin , Esophageal Cancer</keyword>
</DOC>